Group sales grew 6% at CER, with Pharmaceuticals and Diagnostics both expanding despite China pricing reforms. Core operating profit rose 10% and Core EPS 9%, driven by strong product performance and cost management. 2026 guidance for mid-single digit sales and high single digit EPS growth is confi…
Group sales grew 6% at CER, with Pharmaceuticals and Diagnostics both expanding despite China pricing reforms. Core operating profit rose 10% and Core EPS 9%, driven by strong product performance and cost management. 2026 guidance for mid-single digit sales and high single digit EPS growth is confirmed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
